Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

By The Northwire Desk — AI Analysis Mar 18, 2026 · 07:08 FRX · 10.715 FENNEC PHARMACEUTICALS INC. J
FRX · Price

Executive Summary

  • Fennec Pharmaceuticals announced it will publish its full‑year and Q4 2025 financial results before the U.S. market opens on Tuesday, March 24, 2026.
  • Management will host a conference call and webcast at 8:30 a.m. ET to discuss the results and business outlook.
  • The announcement provides investors with advance notice of the upcoming earnings release and access details for the live and archived webcast.

Key Details

  • Release Timing: Full‑year and Q4 2025 results will be released before market open on March 24, 2026.
  • Conference Call/Webcast:
  • Date: Tuesday, March 24, 2026
  • Time: 8:30 a.m. Eastern Time
  • Live webcast link: https://edge.media-server.com/mmc/p/3crq898e
  • Participant registration link: https://register-conf.media‑server.com/register/BIb7d9f04377fd4b9cb7b005d167555402
  • Access Instructions: Investors should log onto www.fennecpharma.com, navigate to the News & Events/Event Calendar under Investors & Media, and join at least 15 minutes early to allow for any required software download.
  • Replay Availability: The webcast will be archived on the company website for thirty days after the call.

Notable Quotes

(No executive quotes were included in this release.)

Read the original news release →

More from FENNEC PHARMACEUTICALS INC. J

May 21, 2026 · 18:01

Fennec Pharmaceuticals Clinical Data Supports Adult Expansion Amidst Strong Q1 Revenue Growth

Other May 14, 2026 · 06:30

Fennec Pharmaceuticals Q1 2026 Earnings

Earnings Apr 21, 2026 · 16:30

Fennec Pharmaceuticals

Other Apr 07, 2026 · 07:03

Fennec’s steady stream of real‑world data builds a foundation for label expansion – but near‑term catalysts remain incremental.

Other Mar 24, 2026 · 07:00

Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Earnings Mar 16, 2026 · 08:08

Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation

Other